© 2022 MJH Life Sciences and Medical Economics. All rights reserved.
© 2022 MJH Life Sciences™ and Medical Economics. All rights reserved.
While GlaxoSmithKline recently decided to stop paying doctors to advocate its drugs, it's possible that drug groups could be tempted to reproduce those murky practices in vulnerable emerging markets.